Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection
DOI:
https://doi.org/10.21649/akemu.v30i4.5541Keywords:
Antifungal, fluconazole prophylaxis, fungal prophylaxis invasive fungal infectionAbstract
Background: Preterm and low birth weight infants have an immature immune system that predisposes them to infections. Broad-spectrum antibiotics, steroids, central venous catheters, endotracheal intubation, and abdominal surgery increase the risk of invasive candidiasis. Prophylactic fluconazole therapy may be helpful in the prevention of invasive candida infection.
Objective: To determine the efficacy of prophylactic fluconazole therapy in preterm and very low birth weight infants in the prevention of invasive candida infection.
Methods: A randomized clinical trial (ClinicalTrials.gov ID NCT05848492) was conducted at the Neonatal Unit of Services Hospital Lahore, Pakistan, from May 1st, 2021 to October 31st, 2021. A total of 110 neonates were recruited for the study. Neonates were divided into a fluconazole prophylaxis group and a control group. The efficacy of fluconazole was determined based on its ability to prevent the development of invasive candida infection. Data were collected using an online form created in Google Forms, and analysis was conducted using PSPP version 1.4 for descriptive data and Open Source Epidemiologic Statistics for Public Health (OpenEpi) version 3.0 for calculating p-values.
Results: The majority of the neonates were between 32 to 34 weeks of gestational age. Cesarean section was the most common mode of delivery (58.6%). 50% of the babies had a history of preterm premature rupture of membranes (PPROM). All infants received broad-spectrum antibiotics. 1 neonate in the fluconazole prophylaxis group while 3 neonates in the placebo group developed invasive candidiasis. Statistical analysis using the Yates-corrected chi-square test found no significant difference in preventing invasive candidiasis between the fluconazole group and the control group in the study population.
Conclusion: The study conducted at our center found that prophylactic fluconazole therapy did not show a significant difference in preventing invasive candidiasis in preterm and very low birth weight (VLBW) neonates.
References
Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, Škrlec I. Candida albicans—The virulence factors and clinical manifestations of infection. J Fungi (Basel). 2021;7(2):79.
Benitz WE, Smith PB. Infectious Disease and Pharmacology: Neonatology Questions and Controversies. 1st Ed. 2018;1–292.
Charoo B, Ashraf Y, Bhat J, Qazi I. Systemic Candida infection in preterm babies: experience from a tertiary care hospital of North India. J Clin Neonatol. 2019;8(3):151-4.
Hsu JF, Lai MY, Lee CW, Chu SM, Wu IH, Huang HR, et al. Comparison of the incidence, clinical features and outcomes of invasive candidiasis in children and neonates. BMC Infect Dis. 2018;18(1):194
Soans S, Mihalyi A, Berlaimont V, Kolhapure S, Dash R, Agrawal A. Vaccination in preterm and low birth weight infants in India. Hum Vaccin Immunother.2021;18(1):1-12.
De Rose DU, Santisi A, Ronchetti MP, Martini L, Serafini L, Betta P, et al. Invasive Candida infections in neonates after major surgery: current evidence and new directions. Pathogens. 2021;10(3):319.
Sousa RA, Oliveira Diniz LM, Lapa Marinho FE, Rezende LG, Carellos EM, Maia de Castro Romanelli R. Risk factors for candidemia in neonates: Systematic review and meta-analysis. Journal of Neonatal Nursing. 2022;28(2):83–92.
Xie J, Zeng J, Zheng S. The efficacy and safety of fluconazole in preventing invasive fungal infection in very low birth weight infants: a systematic review and meta-analysis. Ital J Pediatr. 2023;49(1):51.
Khan EA, Choudhry S, Fatima M, Batool Z. Clinical spectrum, management and outcome of neonatal candidiasis. J Pak Med Assoc.2015;65(1):38-42.
Afzal MF, Abbas E, Hamid MH, Nasir H, Laeeq A, Hanif A. Risk factors for candidaemia in neonates with sepsis in a tertiary care hospital in Pakistan. J Pak Med Assoc. 2020;70(9):1568-1571
MohdYunus VA, Tomer P, Gupta P, Upadhyay A. Epidemiology, clinical spectrum and outcomes of fungal sepsis in neonates in neonatal intensive care unit: a prospective observational study. Int J Contemp Med Res. 2018;5(1):1-5
Dermitzaki N, Baltogianni M, Tsekoura E, Giapros V. Invasive Candida Infections in Neonatal Intensive Care Units: Risk Factors and New Insights in Prevention. Pathogens. 2024;13(8):660.
Fly JH, Kapoor S, Bobo K, Stultz JS. Updates in the Pharmacologic Prophylaxis and Treatment of Invasive Candidiasis in the Pediatric and Neonatal Intensive Care Units. Curr Treat Options Infect Dis. 2022;14:15-34.
Wang XL, Ma Y, Wang S, Dong W, Lei X. A meta-analysis of fluconazole for the prevention of invasive fungal infection in preterm infants. Am J Transl Res. 2021;13(2):434-47.
Tunc G, Toksoz A, Kilicbay F. Candidal Infections in the Neonatal Intensive Care Unit: A Retrospective Observational Study. Med Bull Sisli Etfal Hosp. 2023;57(2):204-209
Nirmal K, Das S, Jothisri L, Jain C, Singh NP. Candida sepsis in neonates a neglected pathogen: study from neonatal intensive care unit tertiary care hospital. Med Mycol. 2022;60(1):367.
Anaraki MR, Nouri-Vaskeh M, Oskoei SA. Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis. Clin Exp Pediatr. 2021;64(4):172-9
Robati Anaraki M, Nouri-Vaskeh M, Abdoli Oskoei S. Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis. Clin Exp Pediatr. 2021;64(4):172-179.
Ferreras-Antolín L, Irwin A, Atra A, Dermirjian A, Drysdale SB, Emonts M, et al. Neonatal antifungal consumption is dominated by prophylactic use; outcomes from the Pediatric Antifungal Stewardship: Optimizing Antifungal Prescription Study. Pediatr Infect Dis J. 2019;38(12):1219-1223.
Daneshnia F, de Almeida Júnior JN, Ilkit M, Lombardi L, Perry AM, Gao M, et al. Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. Lancet Microbe. 2023;4(6):e470–80
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Annals of King Edward Medical University
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk